(119) demonstrated that the combination therapy of erlotinib and MLN0128 (an mTOR inhibitor) effectively reduces the infiltration of immunosuppressive chemokines, such as CCL2 and periostin, as well as TAMs in the TME of glioblastoma, leading to a significant improvement in survival outcomes for glioblastoma mice. Here, MTOR is linked to glioblastoma.